.jpeg)
The efficacy, role and clinical application scope of ruxolitinib (JAKAVI) tablets
Ruxolitinib (JAKAVI), whose scientific name is Ruxolitinib (Ruxolitinib), is a selective inhibitor of Janus
The main effects of ruxolitinib include relieving splenomegaly in patients with myelofibrosis and reducing related symptoms such as fatigue, night sweats and weight loss. It also improves excessive red blood cell proliferation in people with polycythemia vera, reduces the risk of blood clots, and relieves itching and other symptoms. In addition, ruxolitinib has a significant effect on improving the quality of life of patients with myeloproliferative diseases and helping patients return to normal living conditions.
Clinically, ruxolitinib is approved for the treatment of patients with moderate to severe myelofibrosis, including primary myelofibrosis and myelofibrosis secondary to polycythemia vera or chronic myelogenous leukemia. It is also indicated for patients with polycythemia vera that is difficult to control with traditional therapies. Ruxolitinib provides an effective medical treatment option for patients who are not candidates for bone marrow transplantation or who are on the waiting list for bone marrow transplantation.
In general, ruxolitinib, as a JAK1/2 inhibitor, has become an important treatment for patients with myeloproliferative diseases due to its unique mechanism of action and significant clinical efficacy. During use, patients should use the medicine in a standardized manner under the guidance of a doctor, regularly monitor blood and liver and kidney functions, and adjust the treatment plan in a timely manner to obtain the best efficacy and safety.
Reference materials:https://www.drugs.com
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
